Predictors for clinical trial participation in the rare lung disease lymphangioleiomyomatosis

Respiratory Medicine

Volumn 104, Issue 4, 2010, Pages 578-583

  Kinder, Brent W ^a   Sherman, A C ^a   Young, L R ^a   Hagaman, J T ^a   Oprescu, N ^a   Byrnes, S ^b   McCormack, Francis X ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b The LAM Foundation   (United States)

Author keywords

Clinical trial; Lymphangioleiomyomatosis; Rare diseases; Survey; Trial participation

Indexed keywords

ACADEMIC ACHIEVEMENT; ADULT; AGE DISTRIBUTION; ARTICLE; CLINICAL RESEARCH; DISEASE DURATION; HUMAN; LUNG TUMOR; LYMPHANGIOLEIOMYOMATOSIS; MAJOR CLINICAL STUDY; OXYGEN THERAPY; POPULATION RESEARCH; PREDICTOR VARIABLE; PRIORITY JOURNAL; RARE DISEASE; THORAX PAIN; AGE; CLINICAL TRIAL (TOPIC); FEMALE; HEALTH CARE DELIVERY; LUNG DISEASES; METHODOLOGY; MIDDLE AGED; NORTH AMERICA; PATIENT PARTICIPATION; PATIENT SELECTION; QUESTIONNAIRE; RARE DISEASES; STATISTICS AND NUMERICAL DATA;

AGE FACTORS; CLINICAL TRIALS AS TOPIC; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; LUNG DISEASES; LYMPHANGIOLEIOMYOMATOSIS; MIDDLE AGED; NORTH AMERICA; PATIENT PARTICIPATION; PATIENT SELECTION; QUESTIONNAIRES; RARE DISEASES; RESEARCH DESIGN;

EID: 77349095674     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2009.09.023     Document Type: Article

References (17)

1. Cheung A.M., Lee Y., Kapral M., Scher J., Ho I., Lui-Yee D., et al. Barriers and motivations for women to participate in cardiovascular trials. J Obstet Gynaecol Can 30 4 (2008 Apr) 332-337
2. Sharp L., Cotton S.C., Alexander L., Williams E., Gray N.M., and Reid J.M. Reasons for participation and non-participation in a randomized controlled trial: postal questionnaire surveys of women eligible for TOMBOLA (Trial Of Management of Borderline and Other Low-Grade Abnormal smears). Clin Trials 3 5 (2006) 431-442
3. Ding E.L., Powe N.R., Manson J.E., Sherber N.S., and Braunstein J.B. Sex differences in perceived risks, distrust, and willingness to participate in clinical trials: a randomized study of cardiovascular prevention trials. Arch Intern Med 167 9 (2007 May 14) 905-912
4. Fayter D., McDaid C., and Eastwood A. A systematic review highlights threats to validity in studies of barriers to cancer trial participation. J Clin Epidemiol 60 10 (2007 Oct) 990-1001
5. Mathews C., Restivo A., Raker C., Weitzen S., and Disilvestro P. Willingness of gynecologic cancer patients to participate in clinical trials. Gynecol Oncol 112 1 (2009 Jan) 161-165
6. Juvet S.C., McCormack F.X., Kwiatkowski D.J., and Downey G.P. Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans. Am J Respir Cell Mol Biol 36 4 (2007 Apr) 398-408
7. Ryu J.H., Moss J., Beck G.J., Lee J.C., Brown K.K., Chapman J.T., et al. The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med 173 1 (2006 Jan 1) 105-111
8. Johnson S.R., Whale C.I., Hubbard R.B., Lewis S.A., and Tattersfield A.E. Survival and disease progression in UK patients with lymphangioleiomyomatosis. Thorax 59 9 (2004 Sep) 800-803
9. Urban T., Lazor R., Lacronique J., Murris M., Labrune S., Valeyre D., et al. Pulmonary lymphangioleiomyomatosis. A study of 69 patients. Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P). Medicine (Baltimore) 78 5 (1999 Sep) 321-337
10. Matsui K., Beasley M.B., Nelson W.K., Barnes P.M., Bechtle J., Falk R., et al. Prognostic significance of pulmonary lymphangioleiomyomatosis histologic score. Am J Surg Pathol 25 4 (2001 Apr) 479-484
11. McCormack F.X. Lymphangioleiomyomatosis: a clinical update. Chest 133 2 (2008 Feb) 507-516
12. Bissler J.J., McCormack F.X., Young L.R., Elwing J.M., Chuck G., Leonard J.M., et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 358 2 (2008 Jan 10) 140-151
13. Griggs R.C., Batshaw M., Dunkle M., Gopal-Srivastava R., Kaye E., Krischer J., et al. Clinical research for rare disease: opportunities, challenges, and solutions. Mol Genet Metab (2008 Nov 12)
14. Tournoux C., Katsahian S., Chevret S., and Levy V. Factors influencing inclusion of patients with malignancies in clinical trials. Cancer 106 2 (2006 Jan 15) 258-270
15. Mills E.J., Seely D., Rachlis B., Griffith L., Wu P., Wilson K., et al. Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors. Lancet Oncol 7 2 (2006 Feb) 141-148
16. Almoosa K.F., Ryu J.H., Mendez J., Huggins J.T., Young L.R., Sullivan E.J., et al. Management of pneumothorax in lymphangioleiomyomatosis: effects on recurrence and lung transplantation complications. Chest 129 5 (2006 May) 1274-1281
17. Young L.R., Almoosa K.F., Pollock-Barziv S., Coutinho M., McCormack F.X., and Sahn S.A. Patient perspectives on management of pneumothorax in lymphangioleiomyomatosis. Chest 129 5 (2006 May) 1267-1273